# Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

> **NCT01093235** · PHASE3 · UNKNOWN · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 800 (estimated)

## Conditions studied

- Breast Cancer
- Cardiac Toxicity
- Perioperative/Postoperative Complications

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** epirubicin hydrochloride
- **DRUG:** fluorouracil
- **PROCEDURE:** assessment of therapy complications
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** quality-of-life assessment
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT01093235
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-04
- **Primary completion:** 2012-04
- **Final completion:** —
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2010-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093235, "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01093235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*